)

Aclaris Therapeutics (ACRS) investor relations material
Aclaris Therapeutics R&D Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Pipeline overview and program updates
Four clinical programs expected in 2026, including ATI-2138, Bosakitug (ATI-045), ATI-052, and next-generation ITK-selective inhibitors, with additional multispecific antibodies in preclinical development and INDs planned for 2026 and 2027.
Portfolio includes both oral small molecules and biologics, targeting TH1, TH2, and TH17 pathways, with lead assets positioned as potential game changers in multiple indications.
Cash runway extends into the second half of 2028, supporting execution across the portfolio and all planned preclinical and clinical development.
Clinical trial data and development milestones
ATI-2138 (ITK/JAK3 inhibitor) completed Phase 2a in atopic dermatitis with favorable safety and efficacy, advancing to Phase 2 in lichen planus in 1H 2026.
Bosakitug (ATI-045) is in a two-arm, placebo-controlled Phase 2 trial for moderate-to-severe AD, with results expected in 2H 2026; high potency and long half-life demonstrated in Phase 2a.
ATI-052 (bispecific anti-TSLP/IL-4Ra) is in Phase 1a/1b SAD/MAD studies, with top-line results expected in 1Q 2026 and POC trials in asthma and AD planned for 2026.
Centralized photographic review and strict eligibility criteria implemented in dermatology trials to ensure high-quality data and reduce placebo response.
Multiple clinical readouts anticipated across the portfolio in 2026, including ATI-052, Bosakitug, and ATI-2138.
R&D strategy and innovation priorities
Focus on developing best-in-class oral kinase inhibitors and multi-specific antibodies to address unmet needs in immunology and inflammation.
Proprietary KINect platform enables rapid development of kinase inhibitors targeting previously undruggable kinome regions.
Emphasis on high potency, specificity, and innovative mechanisms, including dual and trispecific antibody formats, covalent inhibitors, molecular glues, and protein degraders.
State-of-the-art R&D capabilities in St. Louis support rapid and deep profiling of internal and in-licensed molecules.
Next Aclaris Therapeutics earnings date

Next Aclaris Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage